Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Authors
Andreassen, CRosenstein, B
Kerns, S
Ostrer, H
De Ruysscher, D
Cesaretti, J
Barnett, G
Dunning, A
Dorling, L
West, Catharine M L
Burnet, N
Elliott, R
Coles, C
Hall, E
Fachal, L
Vega, A
Gómez-Caamaño, A
Talbot, C
Symonds, R
De Ruyck, K
Thierens, H
Ost, P
Chang-Claude, J
Seibold, P
Popanda, O
Overgaard, M
Dearnaley, D
Sydes, M
Azria, D
Koch, C
Parliament, M
Blackshaw, M
Sia, M
Fuentes-Raspall, M
Ramon Y Cajal, T
Barnadas, A
Vesprini, D
Gutiérrez-Enríquez, S
Mollà, M
Díez, O
Yarnold, J
Overgaard, J
Bentzen, S
Alsner, J
Affiliation
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.Issue Date
2016-07-18
Metadata
Show full item recordAbstract
Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered study, an individual patient data meta-analysis was carried out by the International Radiogenomics Consortium.Citation
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. 2016: Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2016.06.017PubMed ID
27443449Type
ArticleLanguage
enISSN
1879-0887ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2016.06.017